Quintela Fandiño, Miguel Angel miguel.quintela@uam.es

Actividades

DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy

  • Quintela-Fandino, Miguel
  • Hitt, Ricardo
  • Medina, Pedro P.
  • Gamarra, Soledad
  • Manso, Luis
  • Cortes-Funes, Hernan
  • Sanchez-Cespedes, Montserrat;
... Ver más Contraer

Journal Of Clinical Oncology (p. 4333-4339) - 10/9/2006

10.1200/jco.2006.05.8768 Ver en origen

  • ISSN 0732183X

DOVITINIB LACTATE Multikinase Inhibitor Antiongiogenic Agent Oncolytic

  • Quintela-Fandino
  • M Colomer
  • R

Drugs Of The Future (p. 81-89) - 1/1/2013

10.1358/dof.2013.38.2.1918242 Ver en origen

  • ISSN 03778282

Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets

  • Tusche, Michael W.
  • Ward, Lesley A.
  • Vu, Frances
  • McCarthy, Doug
  • Quintela-Fandino, Miguel
  • Ruland, Jurgen
  • Gommerman, Jennifer L.
  • Mak, Tak W.;
... Ver más Contraer

Journal Of Experimental Medicine (p. 2671-2683) - 23/11/2009

10.1084/jem.20091802 Ver en origen

  • ISSN 00221007

Emerging role of Fatty acid synthase in tumor initiation: implications for cancer prevention

  • Bueno MJ
  • Quintela-Fandino M

Mol Cell Oncol - 3/3/2020

10.1080/23723556.2019.1709389 Ver en origen

  • ISSN 23723556

Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells

  • Bueno, Maria J.
  • Jimenez-Renard, Veronica
  • Samino, Sara
  • Capellades, Jordi
  • Junza, Alejandra
  • Luz Lopez-Rodriguez, Maria
  • Garcia-Carceles, Javier
  • Lopez-Fabuel, Irene
  • Bolanos, Juan P.
  • Chandel, Navdeep S.
  • Yanes, Oscar
  • Colomer, Ramon
  • Quintela-Fandino, Miguel;
... Ver más Contraer

Nature Communications (p. 1-18) - 1/12/2019

10.1038/s41467-019-13028-1 Ver en origen

  • ISSN 20411723

F-18-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial

  • Quintela-Fandino, M.
  • Lluch, A.
  • Manso, L.
  • Calvo, I.
  • Cortes, J.
  • García-Saenz, J.A.
  • Gil-Gil, M.
  • Martinez-Jánez, N.
  • Gonzalez-Martin, A.
  • Adrover, E.
  • De Andres, R.
  • Viñas, G.
  • Llombart-Cussac, A.
  • Alba, E.
  • Guerra, J.
  • Bermejo, B.
  • Zamora, E.
  • Moreno-Anton, F.
  • Simon, S.P.
  • Carrato, A.
  • Lopez-Alonso, A.
  • Escudero, M.J.
  • Campo, R.
  • Carrasco, E.
  • Palacios, J.
  • Mulero, F.
  • Colomer, R.
... Ver más Contraer

Clinical Cancer Research (p. 1432-1441) - 15/3/2017

Editor: American Association for Cancer Research Inc.

10.1158/1078-0432.ccr-16-0738 Ver en origen

  • ISSN 15573265
  • ISSN/ISBN 1557-3265

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1

  • Mouron S, Manso L, Caleiras E, Rodriguez-Peralto JL, Rueda OM, Caldas C, Colomer R, Quintela-Fandino M, Bueno MJ

Breast Cancer Research (p. 21-21) - 1/12/2021

10.1186/s13058-021-01398-8

  • ISSN 14655411
  • iMarina

Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion

  • Mestre-Farrera A
  • Bruch-Oms M
  • Peña R
  • Rodríguez-Morato J
  • Alba-Castellon L
  • Comerma L
  • Quintela-Fandino M
  • Duñach M
  • Baulida J
  • Pozo OJ
  • de Herreros AG
... Ver más Contraer

Cancer Research (p. 438-451) - 15/1/2021

10.1158/0008-5472.can-20-0622 Ver en origen

  • ISSN 00085472

HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1

  • Quintela-Fandino, Miguel
  • Arpaia, Enrico
  • Brenner, Dirk
  • Goh, Theo
  • Yeung, Faith Au
  • Blaser, Heiko
  • Alexandrova, Roumiana
  • Lind, Evan F.
  • Tusche, Mike W.
  • Wakeham, Andrew
  • Ohashi, Pamela S.
  • Mak, Tak W.;
... Ver más Contraer

Proceedings Of The National Academy Of Sciences Of The United States Of America (p. 2622-2627) - 9/2/2010

10.1073/pnas.0914492107 Ver en origen

  • ISSN 10916490

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

  • Quintela-Fandino M
  • Holgado E
  • Manso L
  • Morales S
  • Bermejo B
  • Colomer R
  • Apala JV
  • Blanco R
  • Muñoz M
  • Caleiras E
  • Iranzo V
  • Martinez M
  • Dominguez O
  • Hornedo J
  • Gonzalez-Cortijo L
  • Cortes J
  • Gasol Cudos A
  • Malon D
  • Lopez-Alonso A
  • Moreno-Ortíz MC
  • Mouron S
  • Mañes S
... Ver más Contraer

Breast Cancer Research - 1/12/2020

10.1186/s13058-020-01362-y Ver en origen

  • ISSN 14655411

Este/a investigador/a no tiene libros.

Este/a investigador/a no tiene capítulos de libro.

Phase I clinical trial of neoadjuvant BIBF1120 plus weekly paclitaxel (P) in early HER-2 negative breast cancer. CNIO-BR-01-2010 GEICAM 2010-10 study

  • Quintela-Fandino, M.
  • Urruticoechea, A.
  • Guerra, J.
  • Gil, M.
  • Gonzalez-Martin, A.
  • Marquez, R.
  • Hernandez-Agudo, E.
  • Rodriguez-Martin, C.
  • Gil, M.
  • Bratos, R.
  • Escudero, M. J.
  • Colomer, R.;
... Ver más Contraer

Cancer Research - 15/12/2013

10.1158/0008-5472.sabcs13-pd5-8 Ver en origen

  • ISSN 00085472

Este/a investigador/a no tiene documentos de trabajo.

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K?/?, in Patients with Advanced Solid Tumors

  • Choudhury AD, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, Martin-Liberal J, Linch M, Heath EI, Baird RD, García-Carbacho J, Quintela-Fandino M, Barry ST, de Bruin EC, Colebrook S, Hawkins G, Klinowska T, Maroj B, Moorthy G, Mortimer PG, Moschetta M, Nikolaou M, Sainsbury L, Shapiro GI, Siu LL, Hansen AR

Clinical Cancer Research (p. 2257-2269) - 1/1/2022

10.1158/1078-0432.ccr-21-3087 Ver en origen

  • ISSN 15573265

Este/a investigador/a no tiene proyectos de investigación.

Triple negative breast cancer kinome-taxonomy, prognostic and therapeutics: role of polynucleotide kinase-phosphatase

  • QUINTELA FANDIÑO, MIGUEL ANGEL (Director) Doctorando: Fernández Gaitero, Sara

4/3/2021

  • iMarina

Este/a investigador/a no tiene patentes o licencias de software.

Última actualización de los datos: 18/03/24 14:43